Can-Fite BioPharma Ltd. announced the Israeli Patent Office allowance of patent application No. 284463 covering use of A3 adenosine receptor agonists, including Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders. This expands the company's global IP portfolio for Namodenoson's anti-obesity activity, following similar advancements in the US, Canada, and Australia.
Key takeaways
Israeli Patent Office allowed patent application No. 284463 titled 'An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect' on March 17, 2026.
Patent covers A3AR agonists including Namodenoson for fat loss, obesity, and metabolic disorders.
Follows patent advancements in US, Canada, and Australia.
Peer-reviewed study in International Journal of Obesity demonstrated Namodenoson's anti-obesity effect.
Dr. Pnina Fishman stated it strengthens IP portfolio and positions Namodenoson for development and partnering in obesity market.